Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

Mikkel Andreassen; Caroline Kistorp; Ilan Raymond; Per Hildebrandt; Finn Gustafsson; Lars Østergaard Kristensen; Jens Faber; Mikkel Andreassen; Caroline Kistorp; Ilan Raymond; Per Hildebrandt; Finn Gustafsson; Lars Østergaard Kristensen; Jens Faber

doi:10.1016/j.ghir.2009.03.003

Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

Mikkel Andreassen, Caroline Kistorp, Ilan Raymond, Per Hildebrandt, Finn Gustafsson, Lars Østergaard Kristensen, Jens Faber, Mikkel Andreassen, Caroline Kistorp, Ilan Raymond, Per Hildebrandt, Finn Gustafsson, Lars Østergaard Kristensen, Jens Faber

27 Citations (Scopus)

Abstract

OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.

Original language	English
Journal	Growth Hormone & IGF Research
Volume	19
Issue number	6
Pages (from-to)	486-90
Number of pages	4
ISSN	1096-6374
DOIs	https://doi.org/10.1016/j.ghir.2009.03.003 https://doi.org/10.1016/j.ghir.2009.03.003
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Andreassen, M., Kistorp, C., Raymond, I., Hildebrandt, P., Gustafsson, F., Kristensen, L. Ø., Faber, J., Andreassen, M., Kistorp, C., Raymond, I., Hildebrandt, P., Gustafsson, F., Kristensen, L. Ø., & Faber, J. (2009). Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Hormone & IGF Research, 19(6), 486-90. https://doi.org/10.1016/j.ghir.2009.03.003, https://doi.org/10.1016/j.ghir.2009.03.003

Andreassen, M, Kistorp, C, Raymond, I, Hildebrandt, P, Gustafsson, F, Kristensen, LØ, Faber, J, Andreassen, M, Kistorp, C, Raymond, I, Hildebrandt, P, Gustafsson, F, Kristensen, LØ & Faber, J 2009, 'Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure', Growth Hormone & IGF Research, vol. 19, no. 6, pp. 486-90. https://doi.org/10.1016/j.ghir.2009.03.003, https://doi.org/10.1016/j.ghir.2009.03.003

@article{14caf69064b811df928f000ea68e967b,

title = "Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure",

abstract = "OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.",

author = "Mikkel Andreassen and Caroline Kistorp and Ilan Raymond and Per Hildebrandt and Finn Gustafsson and Kristensen, {Lars {\O}stergaard} and Jens Faber and Mikkel Andreassen and Caroline Kistorp and Ilan Raymond and Per Hildebrandt and Finn Gustafsson and Kristensen, {Lars {\O}stergaard} and Jens Faber",

note = "Keywords: Aged; Case-Control Studies; Chronic Disease; Disease Progression; Female; Heart Failure; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome",

year = "2009",

doi = "10.1016/j.ghir.2009.03.003",

language = "English",

volume = "19",

pages = "486--90",

journal = "Growth Hormone & IGF Research",

issn = "1096-6374",

publisher = "Churchill Livingstone",

number = "6",

}

TY - JOUR

T1 - Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

AU - Andreassen, Mikkel

AU - Kistorp, Caroline

AU - Raymond, Ilan

AU - Hildebrandt, Per

AU - Gustafsson, Finn

AU - Kristensen, Lars Østergaard

AU - Faber, Jens

AU - Andreassen, Mikkel

AU - Kistorp, Caroline

AU - Raymond, Ilan

AU - Hildebrandt, Per

AU - Gustafsson, Finn

AU - Kristensen, Lars Østergaard

AU - Faber, Jens

N1 - Keywords: Aged; Case-Control Studies; Chronic Disease; Disease Progression; Female; Heart Failure; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.

AB - OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.

U2 - 10.1016/j.ghir.2009.03.003

DO - 10.1016/j.ghir.2009.03.003

M3 - Journal article

C2 - 19398211

SN - 1096-6374

VL - 19

SP - 486

EP - 490

JO - Growth Hormone & IGF Research

JF - Growth Hormone & IGF Research

IS - 6

ER -

Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this